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SIGNIFICANCE OF ISOLATED HEPATITIS B CORE ANTIBODY IN BLOOD DONORS FROM SÃO PAULO
Cesar de ALMEIDA NETO(1,2), Edna STRAUSS(3), Esther Cerdeira SABINO(1), Maria Cecília Araripe SUCUPIRA(1) & Dalton de Alencar Fischer CHAMONE(1,2)
SUMMARY
The clinical significance of isolated anti-HBc is still a challenge. To elucidate the real importance of this finding in our blood
donors, an investigation algorithm was tested. One hundred and twelve isolated anti-HBc seropositive blood donors underwent
clinical evaluation and retesting of HBV markers. Those who presented repeatedly reactive isolated anti-HBc, received a single dose
of hepatitis B recombinant vaccine to verify anti-HBs early response. A HBV-DNA determination by PCR was done for those who
did not test positive to anti-HBs after vaccine. The level of anti-HBc was recorded as a ratio of the sample-to-cut-off values (S:C ratio)
in 57 candidates at donation. Comparing true and false-positive anti-HBc results, the different S:C ratios of them were statistically
significant and when less than 2, implying in a false-positive result probability over 80%.
A high percent of false-positive results (16.07%) was verified after anti-HBc retesting. HBV immunity was characterized in
49.11%, either by anti-HBs detection in retesting (15.18%), or after a single dose HBV vaccination (33.93%). HBV-DNA was
negative in all tested donors. In conclusion, this algorithm was useful to clarify the meaning of isolated anti-HBc in most of our blood
donors.
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INTRODUCTION
Post-transfusion hepatitis B is still a relevant subject. Regardless of
all efforts to guarantee safety of blood, hepatitis B residual risk is the
highest among transfusional transmitted diseases, accounting for 1 in
63,000 transfused units34.
Antibody to hepatitis B core antigen (anti-HBc) is the most sensitive
marker of previous hepatitis B contact. It appears in acute phase of HBV
(hepatitis B virus) infection and usually persists after virus clearance15.
Diagnostic problems may arise when anti-HBc is found without HBsAg
or anti-HBs seropositivity19.
Isolated anti-HBc serological profile may be associated with: (a) a
chronic carrier state in which HBsAg is not detectable; (b) remote
infection with loss of measurable anti-HBs; (c) passive transfer of anti-
HBc; (d) nonspecific, cross-reacting antibody; and (e) the period when
HBsAg has disappeared and anti-HBs has not yet been detected14,32.
Hepatitis B vaccination of these individuals has been largely used to
understand the meaning of isolated anti-HBc3,21,24. Those who are immune
will present an anamnestic anti-HBs response, after a single dose of
vaccine12,20.
Introduction of HBV-DNA detection by polymerase chain reaction
(PCR)18 has implemented the confirmation of HBV infection in carriers
with isolated anti-HBc8,17,22,36,39.
The ability to differentiate HBV chronic infection, immunity or false-
positive results in donors with isolated anti-HBc pattern has obvious
significance for the prognosis, treatment and well being of such
individuals32. Thus, this study intends to establish an investigative
algorithm to elucidate the real meaning of isolated anti-HBc on our blood
donors.
PATIENTS AND METHODS
Routines for notification and counseling of blood donors: Once a
blood donor presents a reactive screening serologic test, a letter is sent
inviting him to come back to our institution, for an additional laboratory
testing. When the blood donor screening test presents HBsAg negative
and total anti-HBc positive, the additional laboratory testing will include
HBsAg, anti-HBc and anti-HBs detection. If the additional laboratory
testing reveals an isolated anti-HBc pattern, the blood donor will be asked
to refer to the General Transfusion Research Group of São Paulo University
- Hematology Department, to have this serologic pattern investigated.
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Casuistic: From August 1994 to July 1997, 124 donors with isolated
anti-HBc were enrolled in our protocol at the General Transfusion
Research Group Clinic. Twelve were excluded because they had not
completed the different phases of the protocol. From the 112 individuals
involved, 87 (77.7%) were male and 25 (22.3%) were female, the mean
age was 37.2 years, ranging from 19 to 59. Donors were followed-up
during a minimum period of 30 days, and a maximum of 25 months. On
average, the three phases of the protocol were completed in 120 days.
Inclusion criteria:
a) Blood donors from Fundação Pró-Sangue Hemocentro de São Paulo,
who had the following serologic result after blood screening and
additional laboratory testing:
HBsAg and anti-HBs negative and total anti-HBc positive.
b) Screening serologic tests negative for anti-HCV, anti-HIV, anti-HTLV
I/II, Chagas Disease and Syphilis.
c) Informed consent to participate on this protocol.
Exclusion Criteria:
a) No adherence to the different protocol phases, as it is shown at
Figure 1.
b) Prior Hepatitis B vaccination.
c) Any reference concerning vaccination side effects.
Protocol development: The protocol was developed in three different
phases (Figure 1).
Phase 1
Clinical evaluation: All blood donors underwent a clinical evaluation,
being questioned about their age, gender, race, risk factors to hepatitis B
(tattoos, acupuncture, sexual promiscuity, sexual or household contact
with hepatitis B carriers, receipt of blood transfusion, percutaneous
exposure), previous HBV infection symptoms, alcoholic ingestion,
previous positive blood screening tests to HBV.
Physical examination was routinely carried out in all donors,
searching for suggestive signs of hepatic diseases, including jaundice,
spiders angiomas, hepatomegaly, splenomegaly, ascites, palmar erythema,
gynecomastia (men) and dilated abdominal wall veins.
Additional laboratory testing: In Phase 1, all donors were retested
for: HBsAg, anti-HBc and anti-HBs. After these tests, three different
results were obtained:
1. Anti-HBc negative in the new blood sample. Samples were tested
twice, using the same commercial kit for blood screening at donation.
The blood donation serologic test was considered a false-positive
result.
2. HBsAg negative, both anti-HBc and anti-HBs positive: donor was
informed to be immune to hepatitis B.
3. Persistent isolated anti-HBc positivity: donors underwent phase 2.
Investigation for anti-HBc IgM was also performed in 66 blood
donors at retesting.
Phase 2
Hepatitis B vaccination: Those who were confirmed to be isolated
anti-HBc positive were vaccinated with 20 mg hepatitis B recombinant
single dose vaccine (Engerix B®). After a period of 30 days, another
anti-HBs determination was performed. Those who were anti-HBs
positive (titers over 10 mIU/mL), were informed to be immune.
Phase 3
HBV-DNA research: HBV core/precore DNA detection by
polymerase chain reaction18 was performed in all donors who failed to
produce anti-HBs in phase 2.
Laboratory methods: HBsAg and total anti-HBc – Micro Enzyme
Immunoassay, performed by commercial kit methods (Organon® and
Ortho®).
Anti-HBs - Micro Enzyme Immunoassay, performed by commercial
kit methods (Organon®, Roche® and Murex®). Anti-HBs tests were
considered positive when titers over 10 mIU/mL were detected.
Anti-HBc IgM - Micro Enzyme Immunoassay, performed by
commercial kit methods (Wellcome® and Organon®).
Once a blood sample was tested utilizing one of the commercial kits
above, all the additional samples of that donor were retested using the
same commercial kit.
Sample-to-cut-off ratio (S:C ratio): Only after January 1995 anti-
HBc ratio of the sample-to-cut-off values (S:C ratio) was routinely
incorporated in the serologic result at our institution. Consequently, this
index could only be calculated in 57 donors at donation.
Statistical analyses: The different groups of donors were compared
in relation to the mean of anti-HBc S:C ratio at donation, through the
analysis of variance for independent samples29.
RESULTS
Donors’ clinical data, presented on Table 1, showed that almost 80%
blood donors did not present risk factors for HBV infection. Other data,
such as previous symptoms of hepatitis, alcohol abuse as well as
hepatomegaly, were present in 6.25 to 16% blood donors.
One hundred and twelve blood donors were retested for HBsAg,
total anti-HBc and anti-HBs. None was HBsAg positive at retest, 17
(15.18%) were total anti-HBc and anti-HBs positive and 18 (16.07%)
were negative for all the hepatitis B markers retested. Seventy-seven
blood donors (68.75%) presented repeatedly reactive isolated anti-HBc
and received a single dose of hepatitis B recombinant vaccine. Thirty-
eight donors (33.93%) presented an anamnestic response and 39 did not
test positive to anti-HBs after vaccination. HBV-DNA was performed in
all donors of the last group, and was not detectable in any of them.
Figure 2 shows the four different groups of donors obtained at the end
of the study according to the serologic results shown above.
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Fig. 1 - Protocol development. Fig. 2 - Distribution of the patients on different groups at the end of the protocol.
Table 1
Clinical data in 112 blood donors presenting isolated anti-HBc
n  %
No risk factors for HBV infection 88 78.6
Risk factors for HBV infection 24 21.42
Household contact with HBV carrier 6 5.35
Sexual promiscuity 4 3.57
Tattoo 4 3.57
Receipt of blood transfusion 3 2.67
HBV sexual partner carrier 2 1.78
Percutaneous exposure+blood transfusion 2 1.78
Acupuncture < 12 months 1 0.89
HBV sexual partner carrier+blood transfusion 1 0.89
Domestic contact with HBV carrier+acupuncture
< 12 months 1 0.89
Previous hepatitis symptoms 7 6.25
Alcohol abuse 18 16.07
Previous hepatitis B marker reactivity 1 0.85
Physical examination
Palpable liver 11 9.82
n = number of donors
Anti-HBc IgM detection was performed in 66 blood donors at
retesting, 12 in group I, 11 in group II, 24 in group III and 24 in group
IV. Only 2 blood donors were anti-HBc IgM positive, one in group III
(S:C ratio = 4.1) and one in group IV (S:C ratio = 1.4). Blood donor in
group III was vaccinated with a single dose HBV vaccine, according to
our algorithm. After 30 days, anti-HBc IgM was negative and anti-HBs
was detected. Anti-HBc IgM did not confirm to be positive at retesting
in group IV blood donor. Considering this donor had a anti-HBc IgM
negativity at retesting and the low S:C ratio, the prior anti-HBc IgM
positivity was considered a false-positive result.
Descriptive measures and comparison of the results of 57 donors
anti-HBc S:C ratio, described on Table 2, show a statistically significant
difference of Group II (false-positive anti-HBc) in relation to the others
(p = 0.0001).
DISCUSSION
In our institution, 3.49% of the collected blood units are discarded
due to anti-HBc reactivity, whereas overall discard for HBsAg is only
0.31%. Although most of the discarded anti-HBc positive blood units
are associated with anti-HBs, about 10% of them present isolated anti-
HBc, the meaning of which is still unclear2.
The application of the proposed algorithm enabled the definition of
the significance of anti-HBc in 66.07% of the studied population. In
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15.27%, anti-HBs was detected after retesting. The interpretation could
be either a spontaneous anti-HBs formation or variations of anti-HBs
titers37. Undoubtedly, a young healthy blood donor could be in a hepatitis
B window phase at the time of donation14,32. All the 12 blood donors
from this group that were tested for anti-HBc IgM were negative
concerning this marker. Consequently, variations in anti-HBs titers seem
to have occurred more frequently in this studied group.
The negativity of anti-HBc at the retesting indicates a false-positive
result at donation, found in 18 out of 112 blood donors. Many authors
have observed low specificity for total anti-HBc tests when enzyme
immune assays are used7,16,19,32,33. False-positive results can occur as an
unspecific immature lymphocyte B activation after any infectious
process30. Radioimmunoassay (RIA) is an alternative to improve anti-
HBc specificity27, however the reintroduction of RIA in blood bank
routine does not seem to be plausible, considering the problems in
manipulating radioactive material19. An interesting feature of this group
was the statistically significant low S:C ratio, when compared to the
other groups (p < 0.0001). Most of the donors (83.33%) in group I had
this index lower than 2 at donation, similarly to the results of AOKI et
al.3, who verified that when total anti-HBc S:C index was lower than
2.2, a false-positive result was very likely. Considering that these donors
had a negative anti-HBc at retesting they were advised to reintegrate as
blood donors, according to the institution reentry protocol.
In 33.93% of the studied donors, a typical anamnestic response20
was found after a single dose HBV vaccine. This type of response is
expected in 2% to 34% of isolated anti-HBc individuals3,20,21,24, providing
evidence against chronic infection and enhancing protective immunity12.
Anti-HBc IgM reactivity in one blood donor in this group is not easy to
be interpreted. As it does not seem to be a false positive result, it could
really be due to an acute episode of hepatitis B, that promptly
seroconverted to anti-HBs.
In the proposed algorithm, HBV-DNA was negative in all donors
which persisted isolated positive anti-HBc after retesting and HBV
vaccination. In fact, 39 blood donors remaining isolated anti-HBc positive
were HBV-DNA-negative.
Many authors8,10,17,22,23,31,39 have found chronic HBV carrier state in
isolated anti-HBc individuals when studying the general population. The
algorithm was carried out to identify a sub-population with a higher
probability of being HBV infected. Maybe these objectives were not
achieved, due to a b error, low prevalence of HBV on this population11,35.
Using the same PCR technique in HBsAg negative and anti-HBc positive
blood donors from many Blood Centers in São Paulo State, SUCUPIRA38
found 7 (1.34%) HBV-DNA positive in 522 blood samples. On the other
hand, CRUZ9 found HBV-DNA positivity in 23.3% of São Paulo City
blood donors who had presented previously isolated Hepatitis B core
antibodies. False-negative or false-positive PCR results must be
considered to explain such discrepancy between these studies. The
sensitive of PCR assay to detect the presence of HBV depends upon the
DNA extraction technique, the sequence of primers of the reactions, and
the experimental conditions of the technique13. A better standardization
of PCR assays is necessary to incorporate this technique routinely in
clinical laboratories. This objective is prone to be reach as commercial
kits are available28 and the value of adding genomic amplification testing
to hepatitis B blood donor screening is under investigation1,5,6,26.
Therefore, we could not define the real meaning of isolated anti-
HBc in group IV, considering that HBV-DNA was negative but anti-
HBc was positive, and they were informed that they could not be
reintegrated as blood donors. They are still coming for medical
appointments and the serologic pattern presented before persists.
In order to diminish the loss of blood donated units, one could
consider adopting lower cut-off levels for anti-HBc17,25,27, since test signals
near the cut-off, are judged to be false-positive. This strategy would be
useful mainly in regions with high prevalence of HBV, although more
specific anti-HBc screening assays4 would be more efficacious. Nucleic
acid amplification testing (NAT) of blood donors added to antibody
screening test will certainly reduce the residual risk of post-transfusion
hepatitis B and will help to elucidate some controversial serologic patterns
such as isolated anti-HBc.
RESUMO
Significado do anti-HBc isolado em doadores de sangue
de São Paulo
O significado do anti-HBc isolado continua a ser tema relevante
para aqueles envolvidos com o atendimento a doadores de sangue
soropositivos. Um algoritmo de investigação foi testado com o objetivo
de avaliar em nosso meio o real diagnóstico desses doadores. Cento e
doze doadores com anti-HBc isolado foram submetidos a avaliação
clínico-epidemiológica e testes sorológicos para o VHB. Aqueles
confirmadamente anti-HBc isolado, receberam dose única da vacina
recombinante contra o VHB, e após 30 dias foi pesquisada a formação
do anti-HBs. Naqueles que não formaram anti-HBs após vacina, foi
realizada a pesquisa do HBV-DNA por PCR. O índice do “cut-off” sobre
a densidade ótica foi determinado em 57 indivíduos por ocasião da
doação. Na comparação entre falsos e verdadeiros anti-HBc positivos, o
Table 2
Descriptive measures and comparison of the results among groups – anti-HBc S:C ratio variable at donation
 Variable  Group  n  Minimum  Maximum  Median  Mean  S.D.  p-value
I  7  5.00  8.40  6.00  6.36  1.29
S:C ratio II 12 1.20 5.00 1.30 1.72 1.09 0.0001(*)
III 17 1.70 7.90 5.30 5.68 1.69
IV 21 1.20 9.30 5.20 4.70 2.66
(*) : Analysis of variance; S:C ratio = sample-to-cut-off ratio values; n = number of donors; S.D. = Standard Deviation; p = statistical probability
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índice C.O./D.O. mostrou significância estatística. Assim quando este
índice foi menor que 2, a possibilidade de resultado falso-positivo foi de
83,33%.
Verificamos ainda elevada porcentagem de resultados falsos-positivos
(16,07%) após a simples repetição do anti-HBc. Imunidade ao VHB
pôde ser caracterizada em 49,11%, tanto pela detecção do anti-HBs nos
testes de repetição (15,18%) quanto pela vacinação em dose única contra
a hepatite B (33,93%). O HBV-DNA foi negativo em todos os doadores
testados. Concluímos que este algorítmo foi útil para esclarecer o
significado do anti-HBc isolado na maioria dos doadores de sangue
estudados.
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